Introduction {#s1}
============

Cancer is a complex disease that is not fully understood yet. Cervical cancer is among the most diagnosed type of cancer in women today. Statistically, around 1 out of 154 will be diagnosed for cervical cancer (Siegel et al., [@B55]). The mechanism of cell death and cell survival often intertwines and involves a lot of variables. There is a delicate balance that plays a major role in cell sustenance and the tilt can lean either way, especially in reacting to external substances (Fulda et al., [@B22]). Unfortunately, a viable treatment for treating cervical cancer is yet to be found. Natural-derived molecules have become a promising target in finding the cure for major diseases including diabetes, cancer, and Alzheimer.

*Fritillaria imperialis* or commonly known as "crown imperial" is a species of flower from the Liliaceae family (Khare, [@B31]). This species can be found in various parts of the world specifically Iran, Turkey, Afghanistan, and some parts of the Himalaya (Khare, [@B31]; Badfar-Chaleshtori et al., [@B7]). This plant is considered an ornamental plant due to its large and attractive flowers. It is also known to have several medicinal properties such as becoming a diuretic, treating hypotensive, cardiotonic, and spasmolytic (Khare, [@B31]). There are several interesting molecules that can be extracted from this plant especially steroidal alkaloids (Atta-ur-Rahman et al., [@B5]; Akhtar et al., [@B2]; Khare, [@B31]). Additionally, another class of molecules that can also be extracted from the *F. imperialis* is sesquiterpenes (Atta-ur-Rahman et al., [@B6]). Sesquiterpenes are a class of natural products possessing various biological activities such as antimycobacterial (Abourashed et al., [@B1]), antifungal (Al-Ja\'fari et al., [@B3]), anti-inflammatory, apoptosis-inducing, and immunosuppressant activities (Qi et al., [@B51]). Most of the sesquiterpene lactones impart a wide-range of pharmacological effects, including anti-cancer and immunomodulatory action (Lu et al., [@B38]; Choi et al., [@B14]; Ivanescu et al., [@B28]), antimicrobial, antioxidant, anti-inflammatory, and antinociceptive activities (Sulaiman et al., [@B57]; Dahham et al., [@B18]).

Diterpene Isopimara-7,15-dien-19-oic acid can be isolated from the bulbs of *F. imperialis* plant. The only known activity this molecule has is the prolyl endopeptidase inhibition (Atta-ur-Rahman et al., [@B6]). Other biological or chemical properties of this molecule are yet to be discovered. Thus, the aim of this study is to understand the molecular mechanism of HeLa cells, the most used cervical cancer cell line, upon induction with isopimara-7,15-dien-19-oic acid *in vitro*.

Materials and methods {#s2}
=====================

Plant material and purification of compounds
--------------------------------------------

Isopimara-7,15-dien-19-oic acid (Figure [1](#F1){ref-type="fig"}) was purified from a hexane fraction of Turkish plant *F. imperialis*. The hexane fraction was obtained as thick oil and subjected to column chromatography over silica gel by using acetone/petroleum ether as the solvent system. Isopimara-7,15-dien-19-oic acid was obtained as colorless prismatic crystals with melting point 159--160°C. The detailed extraction procedure and identification of isopimara-7,15-dien-19-oic acid were already published in our previous publication (Atta-ur-Rahman et al., [@B6]).

![**The chemical structure of DIA isolated from the bulbs of ***Fritillaria imperialis*****.](fphar-07-00089-g0001){#F1}

Cell culture
------------

HeLa cells were obtained from the ATCC Collection (ATCC, USA) and were maintained in RPMI-1640 (Sigma, USA) supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin (Gibco, USA). The cells were incubated at 37°C equipped with 5% CO~2~.

MTT
---

The MTT analysis was performed as a preliminary cytotoxic study for DIA against HeLa cells. Cells were seeded in a 96 well plate at a density of 0.8 × 10^5^ cells/ml overnight. Afterwards, the cells were treated with seven different doses of DIA ranging from 30 to 0.64 μg/mL and were left to incubate for 72 h. Upon reaching the allocated incubation time, 20 μl of 5 mg/mL of MTT (Sigma, USA) was added to each of the wells for 4 h at 37°C. Next, the media as well as the MTT were removed and 100 μl of DMSO was added to solubilize the resulting formazon crystals. Subsequently, the reading of the plate was obtained using a microplate reader (Bio-Tek Instruments, USA) at 570 nm.

Cell cycle flow cytometry analysis
----------------------------------

HeLa cells were seeded in 6 well plates at a density of 2.4 × 10^5^ cells/well overnight. The next day, 15 μg/mL of DIA was added into the designated wells and was left to incubate for 72 h in a humidified 37°C CO~2~ incubator. Afterwards, the cells were harvested, fixed in 500 μl of ice cold 80% ethanol and were stored in −20°C for 1 week. On the day of the analysis, the pellet was washed with 1 ml of PBS twice and was permeabilized and stained using 500 μl of RNAse-Propidium Iodide-PBS-Triton X100 for 15 min at room temperature. Next, the cells were analyzed using a FACS Calibur Flow Cytometry machine immediately (BD, USA).

Annexin V-FITC flow cytometry analysis
--------------------------------------

This assay was performed according to the protocol set by the Annexin V/FITC kit by BD, USA. Similar to the cell cycle analysis, HeLa cells were seeded in 6 well plates at a density of 2.4 × 10^5^ cells/well overnight. The next day, 15 μg/mL of DIA was added into the designated wells and was left to incubate for 72 h in a humidified 37°C CO~2~ incubator. After the incubation time, the cells were harvested and washed twice with PBS. The cells were later stained with Annexin V-FITC and Propidium Iodide in 100 μl of 1X Binding Buffer. Then, the cells were analyzed using a FACS Calibur Flow Cytometry machine immediately (BD, USA).

JC-1 flow cytometry analysis
----------------------------

The JC-1 analysis was done using the BD Mitoscreen Kit (BD, USA). Similar to the cell cycle analysis, HeLa cells were seeded in 6 well plates at a density of 2.4 × 10^5^ cells/well overnight. The next day, 15 μg/mL of DIA was added into the designated wells and was left to incubate for 72 h in a humidified 37°C CO~2~ incubator. After the incubation time, the cells were harvested and washed twice with PBS. Afterwards, the cells were stained and incubated with the JC-1 dye for 15 min at 37°C. Then the cells were washed twice with the provided washing buffer. The cells were later analyzed using a FACS Calibur Flow Cytometry machine immediately (BD, USA).

cDNA microarray
---------------

Three sets of biological replicates of untreated HeLa and DIA-treated HeLa were prepared. HeLa cells were seeded in 6 well plates at a density of 2.4 × 10^5^ cells/well overnight. After 24 h, 15 μg/mL of DIA was added into the designated wells and was left to incubate for 48 h in a humidified 37°C CO~2~ incubator. After the incubation time, the cells were harvested and RNA was extracted using the QiagenRneasy Mini Kit (Qiagen, Germany). The quality of the RNA extracted was measured using the 2100 Bioanalyzer using a RNA Pico chip (Agilent, USA). In order to proceed to microarray, the RIN (RNA Integrity Number) should be more than eight. After all of the samples have passed the minimum requirement for microarray analysis the samples were then used for microarray. All of the samples were subjected to the SurePrint G3 Human Gene Expression 8x60K v2 microarray kit (Agilent Technologies, USA) according to manufacturer protocol, and scanned with Agilent DNA microarray scanner. The results from the microarray study has already been uploaded on the Gene Expression Omnibus with the accession number [GSE72974](GSE72974).

Differential expression analysis for microarray
-----------------------------------------------

The results from the microarray analysis were analyzed using the Genespring GX Software Version 13.1 (Agilent, USA). The differential expression comparison was made between the untreated HeLa cells and the DIA-treated HeLa cells. Final results were analyzed based on gene ontology with expression level having *p* \< 0.05.

Quantitative real-time PCR
--------------------------

To validate the results obtained from the microarray study, real-time PCR was performed on the same samples using different sets of primers. Around 1 μg of RNA from each of the samples were converted to cDNA using the Quantitect Reverse Transcription Kit according to the manufacturer\'s protocol (Qiagen, Germany). Then, real-time PCR was conducted using the SYBR Select Master Mix (Invitrogen, USA) on the iCycler IQ5 (Bio-rad, USA). Table [1](#T1){ref-type="table"} illustrates the name of the gene, accession number, and sequence of the primers used in this assay (<http://pga.mgh.harvard.edu/primerbank/>).

###### 

**Accession number and the sequence of the primers used to validate the microarray results**.

  **Gene name**   **Accession number**               **Sequence**
  --------------- ---------------------------------- -------------------------------
  HMOX1           [NM_002133.2](NM_002133.2)         F: 5-AAGACTGCGTTCCTGCTCAAC-3
                                                     R: 5-AAAGCCCTACAGCAACTGTCG-3
  DDIT3           [NM_001195057.1](NM_001195057.1)   F: 5-GAACGGCTCAAGCAGGAAATC-3
                                                     R: 5-TTCACCATTCGGTCAATCAGAG-3
  GPX3            [NM_002084.3](NM_002084.3)         F: 5-AGAGCCGGGGACAAGAGAA-3
                                                     R: 5-ATTTGCCAGCATACTGCTTGA-3
  GADD45A         [NM_001924.3](NM_001924.3)         F: 5-GAGAGCAGAAGACCGAAAGGA-3
                                                     R: 5-CAGTGATCGTGCGCTGACT-3
  ACTB            [NM_001101.3](NM_001101.3)         F: 5-AGAGCTACGAGCTGCCTGAC-3
                                                     R: 5-AGCACTGTGTTGGCGTACAG-3
  GAPDH           [NM_002046.4](NM_002046.4)         F: 5- GGATTTGGTCGTATTGGGC-3
                                                     R: 5- TGGAAGATGGTGATGGGATT-3
  18S RRNA        **[HQ387008.1](HQ387008.1)**       F: 5- GTAACCCGTTGAACCCCATT-3
                                                     R: 5- CCATCCAATCGGTAGTAGCG -3

Proteome profiler array ^TM^
----------------------------

The proteome profiler antibody array was employed to determine the effects of DIA on the activation of several cell stress-related proteins. This assay was done according to the manufacturer\'s protocol. The cell lysates were incubated with the designated membranes overnight at 4°C. The following day, the membranes were washed three times and were then incubated with the freshly prepared antibody cocktail for 2 h. Afterwards, the membranes were washed for three times again, before being incubated with the streptavidin-horseradish-peroxidase for 30 min at room temperature. Then, the membranes were developed under chemiluminescence conditions using the ChemiDOC XRS (Bio-rad, USA).

Superoxide dismutase (SOD) and glutathione (GSH) quantification
---------------------------------------------------------------

Total proteins were extracted from the untreated HeLa and DIA-treated HeLa and were measured using the Bradford assay (Sigma, USA). For SOD, 100 μL of extracted protein was mixed with 200 μL of working solution (0.1 mol/L phosphate buffer, 0.15 mg/mL sodium cyanide in 0.1 mol/L ethylenediaminetetraacetic acid, 1.5 mmol/L nitrobluetetrazolium and 0.12 mmol/L riboflavin). On the other hand, GSH was quantified using Glutathione assay kit (Sigma, USA), where 10 μL of protein was added with 150 μL of working solution (1.5 mg/mL DTNB, 6 U/mL glutathione reductase, and 1 × assay buffer). After 5 min of incubation, 50 μL of NADPH solution (0.16 mg/mL) was added to the mixture. The absorbance for SOD and GSH were measured using ELISA plate reader (Bio-Tek Insturments, USA) at respective wavelengths of 560 and 420 nm.

Statistical analysis
--------------------

All experiments were done in three biological replicates and expressed as mean ± standard deviation. Results with statistical significant (*p* \< 0.05) was assayed by student *t*-test comparing to the untreated control.

Results {#s3}
=======

DIA inhibited the proliferation of HeLa cells and induced apoptosis *in vitro*
------------------------------------------------------------------------------

Based on the MTT results, DIA only showed HeLa cells viability (Figure [1](#F1){ref-type="fig"}) in a dose-dependent manner but not on breast cancer (MCF-7 and MDA-MB231), colon cancer (HT-29), and hepatoblastoma (HepG2) cell lines (results not shown) at concentration up to 30 μg/mL. As in Figure [2](#F2){ref-type="fig"}, the half-maximal inhibitory concentration (IC50) of DIA against HeLa cells after 48 h was 15 μg/mL. Moreover, as in Figure [3A](#F3){ref-type="fig"}, the effects of DIA on HeLa cells was apparent as it induces an increase in the Sub G0/G1 phase. The percentage of cell population in the Sub G0/G1 phase for the untreated HeLa cells was 8.2%, while for the DIA-treated cells was 29.77%. Additionally, as evidenced by the Annexin V assay, DIA-treated HeLa cells had an increase in the early apoptosis and late apoptosis populations, coupled with a decrease in the viable cell population, comparing to the untreated cells. As shown in Figure [3B](#F3){ref-type="fig"}, the percentage of viable cells for the untreated cells was 97.97%, this was followed by a decrease to 33.19% after 48 h of treatment with DIA. For the early apoptosis population, the percentage in the untreated cells was 0.05%, while in the DIA-treated cells, the percentage of the population increased to 34.11%. A similar pattern can also be observed in the late apoptosis population, from 0.02% in the untreated cells to 26.17% in the DIA-treated cells. Furthermore, based on the JC-1 assay, the percentage of monomers in the DIA-treated cells (47.52%) was higher than the untreated cells (5.25%) as displayed in Figure [3C](#F3){ref-type="fig"}.

![**MTT analysis of HeLa cells after being treated with DIA for 48 h at 30 μg/mL followed by seven 2-serial dilutions**.](fphar-07-00089-g0002){#F2}

![**Flow cytometry analysis of (A) Cell cycle analysis by staining the DNA using propidium iodide, (B) Annexin V analysis for the detection of externalization of phosphatidylserine (LL, viable; LR, Early apoptosis; UR, Late apoptosis), and (C) JC-1 analysis for the detecting the change of mitochondrial membrane potential in HeLa cells (Red: Aggregates; Green: Monomers) after 48 h of treatment with 15 μg/mL of DIA**.](fphar-07-00089-g0003){#F3}

DIA regulated cellular stress-related proteins in HeLa cells
------------------------------------------------------------

Figure [4](#F4){ref-type="fig"} illustrates the proteome profiler analysis for cell-stress related proteins as well as the quantification values. DIA-treated cells managed to increase the regulation of several heat shock proteins including hsp27 and hsp70. Moreover, the expression of cytochrome C, SOD2, thioredoxin, carbonic anhydrase IX, p38, and HIF-1a were also increased upon induction with DIA in comparison with the control. The validation of both the microarray and proteome results is presented in Figure [5](#F5){ref-type="fig"}. Similar pattern of expression could be seen for all of the proteins in the proteome to the same genes in the microarray differential analysis.

![**Representative image of the proteome profiler analysis for cell stress-related images as well as the quantification values for HeLa cells; both control (untreated) and DIA-treated cells (15 ug/mL) for 48 h**.](fphar-07-00089-g0004){#F4}

![**Validation of the proteome profiler results by comparing the expression of proteins to the respective genes in microarray (***p***-value for the microarray results are ***p*** \< 0.05)**.](fphar-07-00089-g0005){#F5}

DIA regulated the expression of apoptosis, oxidative stress, and chaperone-related genes
----------------------------------------------------------------------------------------

cDNA microarray study was done to determine the effects of DIA on the mRNA expression of HeLa cells. Based on Table [2](#T2){ref-type="table"}, DIA managed to regulate a large number of genes related to apoptosis, oxidative stress, and heat shock proteins. DIA affected the expression of 96 genes that are involved in either cell death or cell survival.

###### 

**Differentially regulated genes related to oxidative stress and MAPK pathway in HeLa cells after 48 h of treatment with 15 μg/mL DIA with ***p*** \< 0.05**.

  **Accession number**           **Gene symbol**   **Gene name**                                                                         **Log fold change**                            **Regulation**
  ------------------------------ ----------------- ------------------------------------------------------------------------------------- ---------------------------------------------- ----------------
  [NM_002501](NM_002501)         NFIX              Nuclear factor I/X (CCAAT-binding transcription factor)                               2.64                                           Survival
  [NM_000499](NM_000499)         CYP1A1            Cytochrome P450, family 1, subfamily A, polypeptide 1                                 2.38                                           Survival
  [NM_145791](NM_145791)         MGST1             Microsomal glutathione S-transferase 1                                                7.61                                           Survival
  [NM_003998](NM_003998)         NFKB1             Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1                  4.23                                           Survival
  [NM_201397](NM_201397)         GPX1              Glutathione peroxidase 1                                                              3.51                                           Survival
  [NM_000854](NM_000854)         GSTT2             Glutathione S-transferase theta 2                                                     5.67                                           Survival
  [NM_001752](NM_001752)         CAT               Catalase                                                                              3.01                                           Survival
  [NM_002133](NM_002133)         HMOX1             Hemeoxygenase (decycling) 1                                                           2.44                                           Survival
  [NM_001261445](NM_001261445)   TXNRD1            Thioredoxinreductase 1                                                                4.88                                           Survival
  [NM_001270458](NM_001270458)   MAOA              Monoamine oxidase A                                                                   1.56                                           Survival
  [NM_000101](NM_000101)         CYBA              Cytochrome b-245, alpha polypeptide                                                   6.63                                           Survival
  [NM_002084](NM_002084)         GPX3              Glutathione peroxidase 3 (plasma)                                                     --2.59[^\*^](#TN1){ref-type="table-fn"}        Survival
  [NM_006440](NM_006440)         TXNRD2            Thioredoxin reductase 2                                                               2.04                                           Survival
  [NM_138980](NM_138980)         MAPK10            Mitogen-activated protein kinase 10                                                   --3.62[^\*^](#TN1){ref-type="table-fn"}        Survival
  [NM_000379](NM_000379)         XDH               Xanthine dehydrogenase                                                                --1.48[^\*^](#TN1){ref-type="table-fn"}        Survival
  [NM_016931](NM_016931)         NOX4              NADPH oxidase 4                                                                       1.60                                           Survival
  [NM_000454](NM_000454)         SOD1              Superoxide dismutase 1, soluble                                                       9.92                                           Survival
  [NM_201397](NM_201397)         GPX1              Glutathione peroxidase 1                                                              10.58                                          Survival
  [NM_012473](NM_012473)         TXN2              Thioredoxin 2                                                                         2.37                                           Survival
  [NM_002229](NM_002229)         JUNB              Jun B proto-oncogene                                                                  1.05                                           Survival
  [NM_000637](NM_000637)         GSR               Glutathionereductase                                                                  1.99                                           Survival
  [NM_005952](NM_005952)         MT1X              Metallothionein 1X                                                                    5.07                                           Survival
  [NM_001024465](NM_001024465)   SOD2              Superoxide dismutase 2, mitochondrial                                                 2.63                                           Survival
  [NM_006164](NM_006164)         NFE2L2            Nuclear factor, erythroid 2-like 2                                                    --3.82[^\*^](#TN1){ref-type="table-fn"}        Survival
  [NM_001072](NM_001072)         UGT1A6            UDP glucuronosyltransferase 1 family, polypeptide A6                                  2.39                                           Survival
  [NM_001025366](NM_001025366)   VEGFA             Vascular endothelial growth factor A                                                  --5.57[^\*^](#TN1){ref-type="table-fn"}        Survival
  [NM_001216](NM_001216)         CA9               Carbonic anhydrase IX                                                                 1.67                                           Survival
  [NM_004380](NM_004380)         CREBBP            CREB binding protein                                                                  3.67                                           Survival
  [NM_181054](NM_181054)         HIF1A             Hypoxia inducible factor 1, alpha subunit                                             2.67                                           Survival
  [NM_005345](NM_005345)         HSPA1A            Heat shock 70 kDa protein 1A                                                          7.92                                           Survival
  [NM_001540](NM_001540)         HSPB1             Heat shock 27 kDa protein 1                                                           10.71                                          Survival
  [NM_000043](NM_000043)         FAS               Fas cell surface death receptor                                                       1.7873325                                      Death
  [NM_001226](NM_001226)         CASP6             Caspase 6, apoptosis-related cysteine peptidase                                       2.8654807                                      Death
  [NM_003810](NM_003810)         TNFSF10           Tumor necrosis factor (ligand) superfamily, member 10                                 --1.0368137[^\*^](#TN1){ref-type="table-fn"}   
  [NM_021975](NM_021975)         RELA              v-rel avian reticuloendotheliosis viral oncogene homolog A                            1.0848213                                      
  [NM_213566](NM_213566)         DFFA              DNA fragmentation factor, 45kDa, alpha polypeptide                                    1.9827862                                      Death
  [NM_138578](NM_138578)         BCL2L1            BCL2-like 1                                                                           1.5335723                                      Death
  [NM_033306](NM_033306)         CASP4             Caspase 4, apoptosis-related cysteine peptidase                                       1.2512972                                      Death
  [NM_001012271](NM_001012271)   BIRC5             Baculoviral IAP repeat containing 5                                                   7.95958                                        
  [NM_019887](NM_019887)         DIABLO            Diablo, IAP-binding mitochondrial protein                                             5.7222176                                      
  [NM_004346](NM_004346)         CASP3             Caspase 3, apoptosis-related cysteine peptidase                                       5.705864                                       Death
  [NM_002467](NM_002467)         MYC               v-myc avian myelocytomatosis viral oncogene homolog                                   3.997664                                       
  [NM_138764](NM_138764)         BAX               BCL2-associated X protein                                                             1.3814521                                      Death
  [NM_138621](NM_138621)         BCL2L11           BCL2-like 11 (apoptosis facilitator)                                                  1.6899183                                      
  [NM_020529](NM_020529)         NFKBIA            Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha   5.042662                                       
  [NM_058197](NM_058197)         CDKN2A            Cyclin-dependent kinase inhibitor 2A                                                  7.5630064                                      
  [NM_032977](NM_032977)         CASP10            Caspase 10, apoptosis-related cysteine peptidase                                      3.1102889                                      Death
  [NM_000639](NM_000639)         FASLG             Fas ligand (TNF superfamily, member 6)                                                --2.4349697[^\*^](#TN1){ref-type="table-fn"}   Death
  [NM_033355](NM_033355)         CASP8             Caspase 8, apoptosis-related cysteine peptidase                                       2.0166228                                      Death
  [NM_001127184](NM_001127184)   CFLAR             CASP8 and FADD-like apoptosis regulator                                               4.176869                                       Death
  [NM_002392](NM_002392)         MDM2              MDM2 proto-oncogene, E3 ubiquitin protein ligase                                      2.3782425                                      Survival
  [NM_000546](NM_000546)         TP53              Tumor protein p53                                                                     1.6474063                                      Death
  [NM_021138](NM_021138)         TRAF2             TNF receptor-associated factor 2                                                      7.908759                                       Death
  [NM_018947](NM_018947)         CYCS              Cytochrome c, somatic                                                                 6.6717825                                      Death
  [AK094730](AK094730)           HRK               Harakiri, BCL2 interacting protein                                                    1.1366951                                      
  [NM_207002](NM_207002)         BCL2L11           BCL2-like 11 (apoptosis facilitator)                                                  1.0382731                                      Death
  [NM_004346](NM_004346)         CASP3             Caspase 3, apoptosis-related cysteine peptidase                                       1.0135665                                      Death
  [NM_003639](NM_003639)         IKBKG             Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma           5.08775                                        
  [NM_003824](NM_003824)         FADD              Fas (TNFRSF6)-associated via death domain                                             7.09289                                        Death
  [NM_181523](NM_181523)         PIK3R1            Phosphoinositide-3-kinase, regulatory subunit 1 (alpha)                               1.7552358                                      
  [NM_000043](NM_000043)         FAS               Fas cell surface death receptor                                                       1.2629685                                      Death
  [NM_004322](NM_004322)         BAD               BCL2-associated agonist of cell death                                                 6.317196                                       Death
  [NM_021138](NM_021138)         TRAF2             TNF receptor-associated factor 2                                                      2.5242937                                      Death
  [NM_014452](NM_014452)         TNFRSF21          Tumor necrosis factor receptor superfamily, member 21                                 1.2962595                                      
  [NM_003804](NM_003804)         RIPK1             Receptor (TNFRSF)-interacting serine-threonine kinase 1                               1.8435402                                      
  [NM_000612](NM_000612)         IGF2              Insulin-like growth factor 2                                                          --1.0878063[^\*^](#TN1){ref-type="table-fn"}   Survival
  [NM_001188](NM_001188)         BAK1              BCL2-antagonist/killer 1                                                              3.254304                                       
  [NM_000875](NM_000875)         IGF1R             insulin-like growth factor 1 receptor                                                 2.7272189                                      
  [NM_145725](NM_145725)         TRAF3             TNF receptor-associated factor 3                                                      --5.650675[^\*^](#TN1){ref-type="table-fn"}    Death
  [NM_000657](NM_000657)         BCL2              B-cell CLL/lymphoma 2                                                                 --2.1980934[^\*^](#TN1){ref-type="table-fn"}   Death
  [AK309150](AK309150)           BAD               BCL2-associated agonist of cell death                                                 2.1382089                                      Death
  [NM_197966](NM_197966)         BID               BH3 interacting domain death agonist                                                  3.6607141                                      Death
  [NM_002228](NM_002228)         JUN               Jun proto-oncogene                                                                    1.9206382                                      Survival
  [NM_001289072](NM_001289072)   HELLS             Helicase, lymphoid-specific                                                           2.2962887                                      
  [NM_033292](NM_033292)         CASP1             Caspase 1, apoptosis-related cysteine peptidase                                       3.3557472                                      Death
  [NM_003842](NM_003842)         TNFRSF10B         Tumor necrosis factor receptor superfamily, member 10b                                4.5481834                                      Death
  [NM_207002](NM_207002)         BCL2L11           BCL2-like 11 (apoptosis facilitator)                                                  --1.1714572[^\*^](#TN1){ref-type="table-fn"}   Death
  [NM_003789](NM_003789)         TRADD             TNFRSF1A-associated via death domain                                                  5.638668                                       
  [NM_004131](NM_004131)         GZMB              Granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1)          --4.478533[^\*^](#TN1){ref-type="table-fn"}    
  [NM_001229](NM_001229)         CASP9             Caspase 9, apoptosis-related cysteine peptidase                                       4.309328                                       Death
  [NM_003805](NM_003805)         CRADD             CASP2 and RIPK1 domain containing adaptor with death domain                           4.569709                                       Death
  [NM_002392](NM_002392)         MDM2              MDM2 proto-oncogene, E3 ubiquitin protein ligase                                      --1.910822[^\*^](#TN1){ref-type="table-fn"}    Death
  [NM_004031](NM_004031)         IRF7              Interferon regulatory factor 7                                                        4.7208776                                      
  [NM_033338](NM_033338)         CASP7             Caspase 7, apoptosis-related cysteine peptidase                                       4.725479                                       Death
  [NM_001556](NM_001556)         IKBKB             Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta            3.2848263                                      
  [NM_005658](NM_005658)         TRAF1             TNF receptor-associated factor 1                                                      --1.2607836[^\*^](#TN1){ref-type="table-fn"}   Death
  [NM_001278](NM_001278)         CHUK              Conserved helix-loop-helix ubiquitous kinase                                          4.082881                                       
  [NM_003810](NM_003810)         TNFSF10           Tumor necrosis factor (ligand) superfamily, member 10                                 --1.1297648[^\*^](#TN1){ref-type="table-fn"}   
  [NM_181861](NM_181861)         APAF1             Apoptotic peptidase activating factor 1                                               1.063245                                       Death
  [NM_001282669](NM_001282669)   DFFB              DNA fragmentation factor, 40kDa, beta polypeptide (caspase-activated DNase)           1.0859745                                      Death
  [NM_002198](NM_002198)         IRF1              Interferon regulatory factor 1                                                        2.7887836                                      
  [NM_002503](NM_002503)         NFKBIB            Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, beta    2.073728                                       
  [NM_197966](NM_197966)         BID               BH3 interacting domain death agonist                                                  6.265839                                       
  [NM_004324](NM_004324)         BAX               BCL2-associated X protein                                                             1.0556245                                      
  [NM_032515](NM_032515)         BOK               BCL2-related ovarian killer                                                           4.000063                                       
  [NM_001202519](NM_001202519)   CFLAR             CASP8 and FADD-like apoptosis regulator                                               2.3586068                                      Death

*Negative values represent down-regulated genes upon treatment*.

Validation of microarray results with quantitative real-time PCR
----------------------------------------------------------------

To validate the results of differentially regulated genes from the microarray analysis, a set of genes were selected and analyzed using qPCR. All of the validated genes in qPCR had a similar pattern of expression in the microarray results, as presented in Figure [6](#F6){ref-type="fig"}.

![**Validation of the microarray results using quantitative real-time PCR with selected genes in total RNA samples extracted from the control cells and 15 μg/mL DIA-treated cells (***p***-value for the microarray results are ***p*** \< 0.05)**.](fphar-07-00089-g0006){#F6}

DIA-treated cells have a higher amount of SOD and GSH
-----------------------------------------------------

Based on Figure [7](#F7){ref-type="fig"}, the production of both SOD and GSH were elevated in DIA-treated cells comparing to the untreated cells (control). DIA-treated cells have a 1 fold and 1.57 fold change difference respectively from the control cells.

![**Bar chart analysis of the SOD units/mg of protein and μmol GSH/mg of protein in control cells and DIA-treated HeLa cells after 48 h of treatment with 15 μg/mL of DIA**.](fphar-07-00089-g0007){#F7}

Discussion {#s4}
==========

Cellular stress plays an important role in response to chemotherapeutic agents, and this has been one of the major concerns in finding the perfect treatment for cancer, even for cervical cancer (Portt et al., [@B50]; Kim et al., [@B32]). *F. Imperialis* has been long known to possess medicinal properties. The extracts of this plant have not been extensively studied on yet especially on the diterpene group. There are several notable diterpenes that possess promising anti-cancer activities such as carnosol, crispene e, and taxol (Stahlhut et al., [@B56]; Chun et al., [@B15]; Mantaj et al., [@B40]). To the best of our knowledge, the anti-cancer effects of DIA extracted from the bulbs of *F. Imperialis* on HeLa cells has not been reported yet.

There are various phytochemicals that possess anti-cancer properties by modulating the cellular stress pathway (Kim et al., [@B32]). Additionally, there are also several agents used for cancer therapy that cause cellular ROS stress including cisplatin, ascorbic acid, and emodin (Pelicano et al., [@B46]). The cellular stress mechanism is diverged into multiple responses and one of the responses that could be initiated is cell death, including apoptosis (Martindale and Holbrook, [@B41]; Fulda et al., [@B22]; Portt et al., [@B50]). Cell death can be measured through various parameters such as DNA damage through cell cycle analysis, cellular membrane changes, and mitochondrial potential changes (Schmitt et al., [@B53]; Branzei and Foiani, [@B10]). At the molecular level, based on Table [2](#T2){ref-type="table"}, the activation of pro-apoptotic genes is prevalent. The expression of the FADD and FAS gene in DIA-treated cells increased comparing to the control cells. The activation of FADD and FAS triggered a downstream of execution of apoptosis-related proteins such as caspase 8, caspase 3, BID, and JNK (Gupta et al., [@B25]; Clarke and Tyler, [@B16]), which subsequently regulate the BCL2-family proteins. The BCL-2 family is crucial in a cellular response mechanism as it can contribute to the switch of cell death vs. cell survival (Gross et al., [@B24]; Cory et al., [@B17]; Schmitt et al., [@B53]). Pro-apoptotic BCL-2 family genes such as BAX, BAD, and BAK were increased in DIA-treated cells. These proteins can cause mitochondrial dysfunction, which in turns affect the permeability transition pore, increased in radical oxygen species (ROS) and the release of cytochrome C (Gross et al., [@B24]; Cory et al., [@B17]). Cytochrome C is a pro-apoptotic protein that recruits the activation of apaf-1 and caspase 9 (Gross et al., [@B24]; Cory et al., [@B17]). As evidenced by the increase in gene regulation of cytochrome c, apaf-1, and caspase 9, as well as the changes in the mitochondrial membrane potential in the JC-1 assay, DIA treatment induced apoptosis through the mitochondrial pathway. Based on the cell cycle analysis, DIA increased the percentage of population in SubG0/GI which suggests that the treatment may induce DNA fragmentation in the execution of apoptosis. The regulation of the AIF gene and caspase 3 may be involved in the DNA fragmentation process. All these results suggest that DIA induced apoptosis in HeLa cells through DNA fragmentation and mitochondrial membrane potential changes.

Besides cell death, cellular stress response may also trigger the cell survival motion within the cancer cells (Martindale and Holbrook, [@B41]; Fulda et al., [@B22]). Both the protein and gene expression of HSP27 and HSP70 were elevated in HeLa cells upon treatment with DIA, which suggests that the cells were attempting at recovering from the damage induced by regulating these chaperones. The heat shock protein response is a classic retaliation to stress (Feder and Hofmann, [@B20]; Fulda et al., [@B22]; Seigneuric et al., [@B54]; Calderwood et al., [@B13]). Heat shock proteins are a highly conserved set of protein chaperones that promote cell survival in stressful conditions (Calderwood et al., [@B12]; Seigneuric et al., [@B54]). These proteins are known to be overexpressed in cancer especially HSP27, HSP70, and HSP90 (Calderwood et al., [@B12], [@B13]; Seigneuric et al., [@B54]). Hence, there has been development of cancer biomarkers and vaccine for these proteins for the treatment of cancer (Calderwood et al., [@B12], [@B13]; Seigneuric et al., [@B54]). HSP27 and HSP70 were thought to interact in the anti-cell death process as it can inhibit cytochrome c, caspase 9 and eventually the whole apoptotic cascade (Calderwood et al., [@B12]; Fulda et al., [@B22]).

Another reaction to cell stress is the response to oxidative stress (Martindale and Holbrook, [@B41]; Fulda et al., [@B22]; Reuter et al., [@B52]; Portt et al., [@B50]). Based on the microarray and proteome results, DIA managed to induce oxidative stress in HeLa cells upon treatment. The introduction of anti-cancer agents can trigger the production of ROS substantially (Reuter et al., [@B52]; Fiaschi and Chiarugi, [@B21]). The production of ROS is a normal metabolic process in a given cellular system, nevertheless, the balance between ROS and anti-oxidants play a pivotal role in the progression of cancer (Reuter et al., [@B52]; Fiaschi and Chiarugi, [@B21]; Ma, [@B39]). Moreover, the hypoxic conditions of the microenvironment could also contribute to the sustain release of ROS. One of the hallmark of cancer is that cancer cells thrive under hypoxic conditions (Bartrons and Caro, [@B9]). This will usually lead to the activation of HIF1 protein which in turns will affect the accumulation of ROS (Bartrons and Caro, [@B9]; Reuter et al., [@B52]). Additionally, the activation of HIF1 could also affect the activation of carbonic anhydrase IX and VEGFA, which both proteins are inclined to participate in the progression of tumorigenesis (Hui et al., [@B26]; Jubb et al., [@B29]; Dungwa et al., [@B19]). The presence of ROS could affect both the cell death and cell survival mode. One of the pathways that is activated in an oxidative stress state is the KEAP1/NRF-2 stress pathway (Reuter et al., [@B52]; Gorrini et al., [@B23]; Ma, [@B39]). Moreover, the sustained production of ROS will also activate several other signaling pathways such as JNK, MAPK, and ERK pathways. The MAPK pathway could also contribute to the activation of the NRF2 pathway adding to the ROS-mediated initiation of NRF2.

The expression of NRF2-related genes in DIA-induced HeLa cells is significant and this may give way to the underlying mechanism of DIA. The NRF2 is the key player to several antioxidant pathways including the iron sequestration pathway, quinone detoxification, GSH production, and thioredoxin production (Nguyen et al., [@B44]; Gorrini et al., [@B23]; Ma, [@B39]). Once the NRF2 is stimulated it will further activate phase II detoxification enzymes (Kwak and Kensler, [@B34]). The thioredoxin (trx) and glutathione pathway are among the antioxidants pathway that can cross-talk with multiple other pathways and with each other (Brigelius-Flohé et al., [@B11]; Isaac Harris et al., [@B27]; Lu and Holmgren, [@B36]; Vriend and Reiter, [@B61]). Both systems are dependent on NADPH and are involved in the antioxidant defensive mechanism, redox regulation and cell growth (Arnér and Holmgren, [@B4]; Peng et al., [@B48], [@B47]). There are various ways as to how the thioredoxin system contributes toward the progression of cancer (Arnér and Holmgren, [@B4]). There are two trx systems in the mammalian cells; the cytosolic trx and mitochondrial trx (Lu and Holmgren, [@B36]). Both the cytosolic and mitochondrial trx systems are dependent on peroxidases and eventually involved in the redox regulation (Lu and Holmgren, [@B36]). Thioredoxin reductase 1 is known to be overexpressed in most malignant cancer cells (Miyazaki et al., [@B43]; Yoo et al., [@B63]; Karlenius and Tonissen, [@B30]). In fact, besides being involved in the defensive mechanism of cells, thioredoxin peroxidase (TRx) has been reported to inhibit apoptosis by interfering with p53 and p21 (Zhang et al., [@B64]; Ueno et al., [@B59]; Brigelius-Flohé et al., [@B11]). Targeting players of the thioredoxin pathway such as thioredoxin reductase, peroxidase or thioredoxin has been an interest for cancer therapy (Arnér and Holmgren, [@B4]; Lu et al., [@B37]; Karlenius and Tonissen, [@B30]; Penney and Roy, [@B49]). Moreover, in most cancer cells, the level of GSH is often upregulated and can contribute to the drug-resistance mechanism (Balendiran et al., [@B8]; Traverso et al., [@B58]). GSH is a non-protein molecule that has several important physiological properties (Balendiran et al., [@B8]). Moreover, it is known that GSH can contribute toward the initiation of cancer. In phase II detoxification process, GST plays an important role as it assists in the conjugation of GSH with different cancer-promoting electrophiles (Balendiran et al., [@B8]). The high levels of GSH and GST has become one of the important properties in various types of cancer (Balendiran et al., [@B8]). Besides GSH, the level of SOD was also increased in DIA-treated cells. SOD is known to be higher in cancer cells than normal cells (Oberley and Buettner, [@B45]). The role of SOD as an antioxidant is by converting the radical O~2~ to the less radical H~2~O~2~ (Matés, [@B42]; Kowald and Klipp, [@B33]; Valko et al., [@B60]). Catalase, another antioxidant enzyme will later on convert the produced H~2~O~2~ to water and oxygen (Matés, [@B42]; Kowald and Klipp, [@B33]; Valko et al., [@B60];). Additionally, the GPx enzyme will also convert H~2~O~2~ to water and GSSG (Matés, [@B42]; Valko et al., [@B60]). Another important phase II detoxification enzyme is the pro-survival HMOX-1, which is heavily involved in the inactivation of the pro-oxidant heme to ferrous iron, carbon monoxide and bilirubin (Lau et al., [@B35]; Yim et al., [@B62]). Activation of heat shock protein and antioxidant mechanism by this diterpene may protect the cancer cell and thus reduce the killing efficacy of DIA. Overall, Figure [8](#F8){ref-type="fig"} summarizes the proposed schematic of mechanism of action of DIA in HeLa cells.

![**Proposed schematic of the mechanism of action of DIA in HeLa cells by regulating both the anti- and pro-survival pathways**.](fphar-07-00089-g0008){#F8}

Conclusion {#s5}
==========

Overall, DIA managed to induce cellular stress in HeLa cells as evidenced by the results above. DIA induced cellular death via the apoptosis pathway by regulating the FAS and BCL-2 family genes. On the other hand, DIA also activated several pro-survival pathways including the heat shock protein response and anti-oxidant pathways. The dual regulation of DIA in HeLa cells could further benefit the understanding to the molecular mechanism of DIA. Future work using this compound can be applied in an *in vivo* setting to promote a deeper understanding of the function of DIA as an anti-cancer agent.
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